Amoun Pharma may be Saudi, Abu Dhabi Wealth Funds’ next target

Amoun Pharma could be the target of a joint acquisition bid by the Emirati and Saudi sovereign wealth funds, who are said to be eyeing Bausch Health’s unit in Egypt as part of a larger, longer-term partnership, according to Bloomberg

There were no details on the timeline or value of the potential transaction.

Last month Bloomberg noticed Abu Dhabi’s sovereign wealth fund could buy Amoun Pharma north of $ 700 mn.

Bausch — back before it rebranded to sidestep the tarnished Valeant name — acquired Amoun, which manufactures human and veterinary meds, in 2015 for $800 mn and some contingency payments.